767 related articles for article (PubMed ID: 19149849)
1. Central venous access devices for paediatric patients with haemophilia: a single-institution experience.
Titapiwatanakun R; Moir C; Pruthi RK; Stavlo PL; Schmidt KA; Rodriguez V
Haemophilia; 2009 Jan; 15(1):168-74. PubMed ID: 19149849
[TBL] [Abstract][Full Text] [Related]
2. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.
Komvilaisak P; Connolly B; Naqvi A; Blanchette V
Haemophilia; 2006 Dec; 12 Suppl 6():87-93. PubMed ID: 17123400
[TBL] [Abstract][Full Text] [Related]
3. Central venous access catheters in children with haemophilia.
Blanchette VS; al-Musa A; Stain AM; Filler RM; Ingram J
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S39-44. PubMed ID: 8735796
[TBL] [Abstract][Full Text] [Related]
4. Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia.
Jeng MR; O'Brien M; Wong W; Zoland J; Lea J; Tang N; Glader B
Haemophilia; 2009 Nov; 15(6):1272-80. PubMed ID: 19601989
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters.
Mancuso ME; Mannucci PM; Sartori A; Agliardi A; Santagostino E
Br J Haematol; 2008 May; 141(5):689-95. PubMed ID: 18410458
[TBL] [Abstract][Full Text] [Related]
6. Central venous access device-related infections in patients with haemophilia.
Yeoh ZH; Furmedge J; Ekert J; Crameri J; Curtis N; Barnes C
J Paediatr Child Health; 2013 Mar; 49(3):242-5. PubMed ID: 23438133
[TBL] [Abstract][Full Text] [Related]
7. Use of implantable venous access devices in children with severe hemophilia: benefits and burden.
Van Dijk K; Van Der Bom JG; Bax KN; Van Der Zee DC; Van Den Berg MH
Haematologica; 2004 Feb; 89(2):189-94. PubMed ID: 15003894
[TBL] [Abstract][Full Text] [Related]
8. Central venous access devices in children with hemophilia: an update.
Blanchette VS; Al-Musa A; Stain AM; Ingram J; Fille RM
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S11-4. PubMed ID: 9351530
[TBL] [Abstract][Full Text] [Related]
9. Consensus recommendations for use of central venous access devices in haemophilia.
Ewenstein BM; Valentino LA; Journeycake JM; Tarantino MD; Shapiro AD; Blanchette VS; Hoots WK; Buchanan GR; Manco-Johnson MJ; Rivard GE; Miller KL; Geraghty S; Maahs JA; Stuart R; Dunham T; Navickis RJ
Haemophilia; 2004 Sep; 10(5):629-48. PubMed ID: 15357790
[TBL] [Abstract][Full Text] [Related]
10. Fatal central venous catheter-related infection in haemophilia.
Crary SE; Buchanan GR; Journeycake JM
Haemophilia; 2006 Mar; 12(2):183-6. PubMed ID: 16476095
[TBL] [Abstract][Full Text] [Related]
11. Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS).
Langley AR; Stain AM; Chan A; McLimont M; Chait S; Wu J; Poon MC; Card R; Israels SJ; Laferriere N; Klaassen RJ; Rivard GE; Cloutier S; Hawes S; Feldman B; Blanchette V
Haemophilia; 2015 Jul; 21(4):469-76. PubMed ID: 26104147
[TBL] [Abstract][Full Text] [Related]
12. Ethanol lock therapy for the treatment of catheter-related infections in haemophilia patients.
Rajpurkar M; Boldt-Macdonald K; McLenon R; Callaghan MU; Chitlur M; Lusher JM; Becker C
Haemophilia; 2009 Nov; 15(6):1267-71. PubMed ID: 19659937
[TBL] [Abstract][Full Text] [Related]
13. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
[TBL] [Abstract][Full Text] [Related]
14. Central venous access device associated infections: recommendations for best practice in home infusion therapy.
Gorski LA
Home Healthc Nurse; 2010 Apr; 28(4):221-9. PubMed ID: 20520262
[TBL] [Abstract][Full Text] [Related]
15. Central venous access device infections in children with hemophilia: a comparison of prophylaxis and episodic therapy.
Hacker MR; Page JH; Shapiro AD; Rich-Edwards JW; Manco-Johnson MJ
J Pediatr Hematol Oncol; 2007 Jul; 29(7):458-64. PubMed ID: 17609623
[TBL] [Abstract][Full Text] [Related]
16. The use of central venous catheters in haemophilia patients.
Izzi G; Franchini M; Bonetti L; Tagliaferri A
Haemophilia; 2010 Jan; 16 Suppl 1():29-31. PubMed ID: 20059567
[TBL] [Abstract][Full Text] [Related]
17. Complications of central venous access devices in paediatric haemophilia patients.
Domm JA; Hudson MG; Janco RL
Haemophilia; 2003 Jan; 9(1):50-6. PubMed ID: 12558778
[TBL] [Abstract][Full Text] [Related]
18. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
19. Venous access in haemophilic children: choice and management.
Santagostino E; Mancuso ME
Haemophilia; 2010 Jan; 16 Suppl 1():20-4. PubMed ID: 20059565
[TBL] [Abstract][Full Text] [Related]
20. Surveillance of infectious complications associated with central venous access devices in children with haemophilia.
Tarantino MD; Lail A; Donfield SM; Lynn H; Peddle L; Hunsberger S; Shapiro AD
Haemophilia; 2003 Sep; 9(5):588-92. PubMed ID: 14511299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
